File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A multicentre randomized controlled trial of oral misoprostol and i.m. syntometrine in the management of the third stage of labour

TitleA multicentre randomized controlled trial of oral misoprostol and i.m. syntometrine in the management of the third stage of labour
Authors
Issue Date2001
PublisherOxford University Press. The Journal's web site is located at http://humrep.oxfordjournals.org/
Citation
Human Reproduction, 2001, v. 16 n. 1, p. 31-35 How to Cite?
AbstractPostpartum haemorrhage accounts for nearly 28% of maternal mortality in developing countries. Syntometrine is an effective and commonly used oxytocic in preventing postpartum haemorrhage, but it requires a controlled storage environment and i.m. administration. Misoprostol is an orally active uterotonic agent. A total of 2058 patients having a singleton pregnancy, low risk for postpartum haemorrhage and vaginal delivery were randomized to receive either 1 ml syntometrine or 600 μg misoprostol for the management of the third stage of labour. There were no significant differences between the two groups in the mean blood loss, the incidence of postpartum haemorrhage and the fall in haemoglobin concentration. The need for additional oxytocic injection was significantly higher in the misoprostol group [relative risk (RR) 1.62, 95% confidence interval (CI) 1.34-1.96], but that of manual removal of placenta was reduced (RR 0.29, 95% CI 0.09-0.87). Shivering and transient pyrexia were more common in the misoprostol group. Oral misoprostol might be used in the management of the third stage, especially in situations where the use of syntometrine is contraindicated and facilities for storage and parenteral administration of oxytocics are limited.
Persistent Identifierhttp://hdl.handle.net/10722/184203
ISSN
2015 Impact Factor: 4.621
2015 SCImago Journal Rankings: 2.271
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorNg, PSen_US
dc.contributor.authorChan, ASMen_US
dc.contributor.authorSin, WKen_US
dc.contributor.authorTang, LCHen_US
dc.contributor.authorCheung, KBen_US
dc.contributor.authorYuen, PMen_US
dc.date.accessioned2013-06-25T03:01:15Z-
dc.date.available2013-06-25T03:01:15Z-
dc.date.issued2001en_US
dc.identifier.citationHuman Reproduction, 2001, v. 16 n. 1, p. 31-35en_US
dc.identifier.issn0268-1161en_US
dc.identifier.urihttp://hdl.handle.net/10722/184203-
dc.description.abstractPostpartum haemorrhage accounts for nearly 28% of maternal mortality in developing countries. Syntometrine is an effective and commonly used oxytocic in preventing postpartum haemorrhage, but it requires a controlled storage environment and i.m. administration. Misoprostol is an orally active uterotonic agent. A total of 2058 patients having a singleton pregnancy, low risk for postpartum haemorrhage and vaginal delivery were randomized to receive either 1 ml syntometrine or 600 μg misoprostol for the management of the third stage of labour. There were no significant differences between the two groups in the mean blood loss, the incidence of postpartum haemorrhage and the fall in haemoglobin concentration. The need for additional oxytocic injection was significantly higher in the misoprostol group [relative risk (RR) 1.62, 95% confidence interval (CI) 1.34-1.96], but that of manual removal of placenta was reduced (RR 0.29, 95% CI 0.09-0.87). Shivering and transient pyrexia were more common in the misoprostol group. Oral misoprostol might be used in the management of the third stage, especially in situations where the use of syntometrine is contraindicated and facilities for storage and parenteral administration of oxytocics are limited.en_US
dc.languageengen_US
dc.publisherOxford University Press. The Journal's web site is located at http://humrep.oxfordjournals.org/en_US
dc.relation.ispartofHuman Reproductionen_US
dc.subject.meshAdministration, Oralen_US
dc.subject.meshAdulten_US
dc.subject.meshErgonovine - Administration & Dosageen_US
dc.subject.meshFemaleen_US
dc.subject.meshHemoglobins - Analysisen_US
dc.subject.meshHumansen_US
dc.subject.meshInjections, Intramuscularen_US
dc.subject.meshLabor Stage, Third - Drug Effectsen_US
dc.subject.meshMisoprostol - Administration & Dosageen_US
dc.subject.meshOxytocics - Administration & Dosageen_US
dc.subject.meshOxytocin - Administration & Dosageen_US
dc.subject.meshPostpartum Hemorrhage - Prevention & Controlen_US
dc.subject.meshPregnancyen_US
dc.titleA multicentre randomized controlled trial of oral misoprostol and i.m. syntometrine in the management of the third stage of labouren_US
dc.typeArticleen_US
dc.identifier.emailTang, LCH: lchtang@hku.hken_US
dc.identifier.authorityTang, LCH=rp01756en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1093/humrep/16.1.31-
dc.identifier.pmid11139532-
dc.identifier.scopuseid_2-s2.0-0035191255en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0035191255&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume16en_US
dc.identifier.issue1en_US
dc.identifier.spage31en_US
dc.identifier.epage35en_US
dc.identifier.isiWOS:000166463700007-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridNg, PS=7201377018en_US
dc.identifier.scopusauthoridChan, ASM=18533817000en_US
dc.identifier.scopusauthoridSin, WK=36752630100en_US
dc.identifier.scopusauthoridTang, LCH=7402081111en_US
dc.identifier.scopusauthoridCheung, KB=7402406620en_US
dc.identifier.scopusauthoridYuen, PM=20236675500en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats